V-Wave
V-Wave was established with a focus on developing a percutaneous implantable shunt for patients with chronic heart failure. Its leading product, the V-Wave Ventura Interatrial Shunt, is an investigational device that has received Breakthrough Device Designation from the FDA and CE Marking in the EU. The company was acquried by Johnson & Johnson (NYSE: JNJ) in 2024.